Homology Medicines, a preclinical biotech developing a gene therapy delivery platform for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Bedford, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol FIXX. Homology Medicines filed confidentially on December 22, 2017. BofA Merrill Lynch, Cowen & Company and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
